Cargando…
Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways
Statins inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme and are the most widely used medication for hypercholesterolemia. Previous studies on the metabolite signature of simvastatin treatment have included only a small number of metabolites. We performed a high-throughput liquid chromato...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414498/ https://www.ncbi.nlm.nih.gov/pubmed/36005625 http://dx.doi.org/10.3390/metabo12080753 |